PubMed:17959715 / 1663-2021 JSONTXT

{"project":"LitCoin-entities","denotations":[{"id":"4483","span":{"begin":4,"end":8},"obj":"GeneOrGeneProduct"},{"id":"4484","span":{"begin":59,"end":62},"obj":"DiseaseOrPhenotypicFeature"},{"id":"4485","span":{"begin":94,"end":97},"obj":"DiseaseOrPhenotypicFeature"},{"id":"4486","span":{"begin":231,"end":234},"obj":"DiseaseOrPhenotypicFeature"},{"id":"4487","span":{"begin":305,"end":313},"obj":"OrganismTaxon"}],"attributes":[{"id":"A31","pred":"db_id","subj":"4483","obj":"NCBIGene:4292"},{"id":"A32","pred":"db_id","subj":"4484","obj":"MESH:D015470"},{"id":"A33","pred":"db_id","subj":"4485","obj":"MESH:D015470"},{"id":"A34","pred":"db_id","subj":"4486","obj":"MESH:D015470"},{"id":"A35","pred":"db_id","subj":"4487","obj":"NCBITaxon:9606"}],"namespaces":[{"prefix":"_base","uri":"https://w3id.org/biolink/vocab/"},{"prefix":"MESH","uri":"http://id.nlm.nih.gov/mesh/"},{"prefix":"NCBITaxon","uri":"https://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?id="},{"prefix":"NCBIGene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"OMIM","uri":"https://www.omim.org/entry/"},{"prefix":"DBSNP","uri":"https://www.ncbi.nlm.nih.gov/snp/"}],"text":"The MLH1 -93 variant allele was also over-represented in t-AML cases when compared to de novo AML cases (36.9%, n = 420) and healthy controls (36.3%, n = 952), and was associated with a significantly increased risk of developing t-AML (odds ratio 5.31, 95% confidence interval 1.40 to 20.15), but only in patients previously treated with a methylating agent."}

{"project":"LitCoin-sentences","denotations":[{"id":"T12","span":{"begin":0,"end":358},"obj":"Sentence"}],"text":"The MLH1 -93 variant allele was also over-represented in t-AML cases when compared to de novo AML cases (36.9%, n = 420) and healthy controls (36.3%, n = 952), and was associated with a significantly increased risk of developing t-AML (odds ratio 5.31, 95% confidence interval 1.40 to 20.15), but only in patients previously treated with a methylating agent."}

{"project":"LitCoin-GeneOrGeneProduct-v0","denotations":[{"id":"T25","span":{"begin":4,"end":8},"obj":"GeneOrGeneProduct"},{"id":"T26","span":{"begin":57,"end":62},"obj":"GeneOrGeneProduct"},{"id":"T27","span":{"begin":63,"end":68},"obj":"GeneOrGeneProduct"},{"id":"T28","span":{"begin":98,"end":103},"obj":"GeneOrGeneProduct"},{"id":"T29","span":{"begin":154,"end":157},"obj":"GeneOrGeneProduct"},{"id":"T30","span":{"begin":229,"end":234},"obj":"GeneOrGeneProduct"}],"text":"The MLH1 -93 variant allele was also over-represented in t-AML cases when compared to de novo AML cases (36.9%, n = 420) and healthy controls (36.3%, n = 952), and was associated with a significantly increased risk of developing t-AML (odds ratio 5.31, 95% confidence interval 1.40 to 20.15), but only in patients previously treated with a methylating agent."}

{"project":"LitCoin-GeneOrGeneProduct-v2","denotations":[{"id":"T14","span":{"begin":4,"end":8},"obj":"GeneOrGeneProduct"},{"id":"T15","span":{"begin":154,"end":157},"obj":"GeneOrGeneProduct"}],"text":"The MLH1 -93 variant allele was also over-represented in t-AML cases when compared to de novo AML cases (36.9%, n = 420) and healthy controls (36.3%, n = 952), and was associated with a significantly increased risk of developing t-AML (odds ratio 5.31, 95% confidence interval 1.40 to 20.15), but only in patients previously treated with a methylating agent."}

{"project":"LitCoin-GeneOrGeneProduct-v3","denotations":[{"id":"T8","span":{"begin":4,"end":8},"obj":"GeneOrGeneProduct"},{"id":"T9","span":{"begin":154,"end":157},"obj":"GeneOrGeneProduct"}],"text":"The MLH1 -93 variant allele was also over-represented in t-AML cases when compared to de novo AML cases (36.9%, n = 420) and healthy controls (36.3%, n = 952), and was associated with a significantly increased risk of developing t-AML (odds ratio 5.31, 95% confidence interval 1.40 to 20.15), but only in patients previously treated with a methylating agent."}

{"project":"LitCoin_Mondo_095","denotations":[{"id":"T11","span":{"begin":59,"end":62},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T12","span":{"begin":94,"end":97},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T13","span":{"begin":231,"end":234},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A11","pred":"mondo_id","subj":"T11","obj":"0018874"},{"id":"A12","pred":"mondo_id","subj":"T12","obj":"0018874"},{"id":"A13","pred":"mondo_id","subj":"T13","obj":"0018874"}],"text":"The MLH1 -93 variant allele was also over-represented in t-AML cases when compared to de novo AML cases (36.9%, n = 420) and healthy controls (36.3%, n = 952), and was associated with a significantly increased risk of developing t-AML (odds ratio 5.31, 95% confidence interval 1.40 to 20.15), but only in patients previously treated with a methylating agent."}

{"project":"LitCoin-MeSH-Disease-2","denotations":[{"id":"T18","span":{"begin":59,"end":62},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T19","span":{"begin":94,"end":97},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T20","span":{"begin":231,"end":234},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A18","pred":"ID:","subj":"T18","obj":"DISEASE"},{"id":"A19","pred":"ID:","subj":"T19","obj":"DISEASE"},{"id":"A20","pred":"ID:","subj":"T20","obj":"DISEASE"}],"text":"The MLH1 -93 variant allele was also over-represented in t-AML cases when compared to de novo AML cases (36.9%, n = 420) and healthy controls (36.3%, n = 952), and was associated with a significantly increased risk of developing t-AML (odds ratio 5.31, 95% confidence interval 1.40 to 20.15), but only in patients previously treated with a methylating agent."}

{"project":"LitCoin-MONDO_bioort2019","denotations":[{"id":"T18","span":{"begin":59,"end":62},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T19","span":{"begin":94,"end":97},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T20","span":{"begin":231,"end":234},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A18","pred":"#label","subj":"T18","obj":"DISEASE"},{"id":"A19","pred":"#label","subj":"T19","obj":"DISEASE"},{"id":"A20","pred":"#label","subj":"T20","obj":"DISEASE"}],"text":"The MLH1 -93 variant allele was also over-represented in t-AML cases when compared to de novo AML cases (36.9%, n = 420) and healthy controls (36.3%, n = 952), and was associated with a significantly increased risk of developing t-AML (odds ratio 5.31, 95% confidence interval 1.40 to 20.15), but only in patients previously treated with a methylating agent."}

{"project":"LitCoin-NCBITaxon-2","denotations":[{"id":"T7","span":{"begin":305,"end":313},"obj":"OrganismTaxon"}],"text":"The MLH1 -93 variant allele was also over-represented in t-AML cases when compared to de novo AML cases (36.9%, n = 420) and healthy controls (36.3%, n = 952), and was associated with a significantly increased risk of developing t-AML (odds ratio 5.31, 95% confidence interval 1.40 to 20.15), but only in patients previously treated with a methylating agent."}

{"project":"LitCoin-training-merged","denotations":[{"id":"T9","span":{"begin":154,"end":157},"obj":"GeneOrGeneProduct"},{"id":"T8","span":{"begin":4,"end":8},"obj":"GeneOrGeneProduct"},{"id":"T20","span":{"begin":231,"end":234},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T19","span":{"begin":94,"end":97},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T18","span":{"begin":59,"end":62},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T80947","span":{"begin":305,"end":313},"obj":"OrganismTaxon"}],"attributes":[{"id":"A18","pred":"#label","subj":"T18","obj":"DISEASE"},{"id":"A19","pred":"#label","subj":"T19","obj":"DISEASE"},{"id":"A20","pred":"#label","subj":"T20","obj":"DISEASE"}],"text":"The MLH1 -93 variant allele was also over-represented in t-AML cases when compared to de novo AML cases (36.9%, n = 420) and healthy controls (36.3%, n = 952), and was associated with a significantly increased risk of developing t-AML (odds ratio 5.31, 95% confidence interval 1.40 to 20.15), but only in patients previously treated with a methylating agent."}

{"project":"PMID_GLOBAL","denotations":[{"id":"T11","span":{"begin":59,"end":62},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T12","span":{"begin":94,"end":97},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T13","span":{"begin":231,"end":234},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A11","pred":"mondo_id","subj":"T11","obj":"0018874"},{"id":"A12","pred":"mondo_id","subj":"T12","obj":"0018874"},{"id":"A13","pred":"mondo_id","subj":"T13","obj":"0018874"}],"text":"The MLH1 -93 variant allele was also over-represented in t-AML cases when compared to de novo AML cases (36.9%, n = 420) and healthy controls (36.3%, n = 952), and was associated with a significantly increased risk of developing t-AML (odds ratio 5.31, 95% confidence interval 1.40 to 20.15), but only in patients previously treated with a methylating agent."}